Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
16.7M
-
Number of holders
-
18
-
Total 13F shares, excl. options
-
375K
-
Shares change
-
+40.5K
-
Total reported value, excl. options
-
$1.53M
-
Value change
-
+$203K
-
Number of buys
-
9
-
Number of sells
-
-4
-
Price
-
$4.10
Significant Holders of VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE) as of Q2 2023
22 filings reported holding VYNE - VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share as of Q2 2023.
VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE) has 18 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 375K shares
of 16.7M outstanding shares and own 2.25% of the company stock.
Largest 10 shareholders include DSC Advisors, L.P. (115K shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (76.4K shares), BlackRock Inc. (49.1K shares), VANGUARD GROUP INC (44.9K shares), RENAISSANCE TECHNOLOGIES LLC (36.1K shares), GEODE CAPITAL MANAGEMENT, LLC (24.9K shares), STATE STREET CORP (11.7K shares), Tekla Capital Management LLC (7.52K shares), BANK OF AMERICA CORP /DE/ (4.2K shares), and MORGAN STANLEY (2.21K shares).
This table shows the top 18 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.